- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03885895
Treatment of Freckles by Intradermal Tranexamic Acid Versus Q Switched KTP Laser.
Comparative Study for the Treatment of Freckles by Intradermal Tranexamic Acid Versus Q Switched KTP Laser (532nm)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
One side of the face will receive QS KTPlaser at a wavelength of 532 nm, spot size 2-3 mm , power 1-1.5J/cm2 and the clinical end point is just frosting.Sessions will be every month for 2 months.
The other side of the face will be assigned to TXA intradermal microinjection in the same session using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on freckles area at.
The sessions of TXA will be every 2 weeks for 2 months.
Postoperatively, topical antibiotic ointment and steriod will be applied. Sunscreen then applied until the next treatment in order to minimize reactive hyperpigmentations.
Follow up after treatment monthly for 2 month.
Studietype
Registrering (Forventet)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Cairo, Egypt, 11956
- Rekruttering
- Kasr El Ainy university hospital
-
Ta kontakt med:
- Samar Tuqan
- Telefonnummer: 02 01003133495
- E-post: samartuqan@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Both genders
- Age group > 18years old.
Exclusion Criteria:
- Pregnant and lactating females.
- Keloid and scarring tendancy
- Usage of invasive or semi invasive procedures for treatment of freckles such as chemical peeling , dermaroller..etc. 2 months prior to the study.
- Oral Isotretinoin 6 months prior to the study.
- Active herpetic lesions.
- Any concurrent active skin disease within the treated area.
- Photosensitive skin conditions such as systemic lupus erythematous.
- History of delayed wound healing.
- Bleeding diathesis.
- Medical conditions such as autoimmune diseases.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Participants with freckles (one side of the face)
one randomized side of the face will be treated by Intradermal Tranexamic acid
|
Ampoules used for intradermal injection
|
|
Aktiv komparator: Participants with freckles (other side of the face)
other side will be treated by Q switched KTP laser
|
LASER
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pigmentation and severity index by clinical evaluation
Tidsramme: 6 months to 1 year
|
Evaluate efficacy of intradermal tranexamic acid versus Q switched KTP laser in the treatment of freckles before treatment, after treatment and after follow-up
|
6 months to 1 year
|
|
Melanin Index change by spectrophotometer
Tidsramme: 6 months to 1 year
|
Evaluate efficacy of intradermal tranexamic acid versus Q switched KTP laser in the treatment of freckles before treatment, after treatment and after follow-up
|
6 months to 1 year
|
|
Blinded observers' evaluation
Tidsramme: 6 months to 1 year
|
Evaluate efficacy of intradermal tranexamic acid versus Q switched KTP laser in the treatment of freckles before treatment, after treatment and after follow-up
|
6 months to 1 year
|
|
Patient satisfaction rate
Tidsramme: 6 months to 1 year
|
Evaluate efficacy of intradermal tranexamic acid versus Q switched KTP laser in the treatment of freckles before treatment, after treatment and after follow-up
|
6 months to 1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- EgyFreckles
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .